Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

Intellia has a collaboration agreement with Regeneron Pharmaceuticals REGN for the development and commercialization of nex-z. Nexiguran ziclumeran is being studied for two indications — ATTR ...

Intellia Therapeutics will cut about 27% of its workforce, or roughly 142 jobs, this year in a cost-savings push intended to support its operations into the first half of 2027, when it expects to ...

Intellia Therapeutics is starting off 2025 ... Both drugs would be entering competitive markets. BioCryst Pharmaceuticals is the most recent entry with Orladeyo, the first oral option to prevent ...

and risks related to Intellia’s collaborations with Regeneron Pharmaceuticals, Inc. or its other collaborations not continuing or not being successful. For a discussion of these and other risks ...

It has been many moons since I last held a position in Intellia Therapeutics, Inc. (NASDAQ:NTLA). At that time, cutting-edge biotech companies going after CAR-T therapies and gene therapies were ...

Ark Invest’s ARK Innovation ETF ARKK purchased a substantial 264,596 shares of Recursion Pharmaceuticals ... closing at a 15.14% decrease on Friday. Intellia Therapeutics announced a 27% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Intellia Therapeutics announced its strategic priorities and key anticipated milestones for 2025. However, investors were disappointed and the stock fell following the announcement. As part of ...